Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer

被引：1
|
作者：
Hasenburg, A. [1 ]
van de Velde, C. J. H. [2 ]
Seynaeve, C. [3 ]
Rea, D. W. [4 ]
Vannetzel, J. [5 ]
Paridaens, R. [6 ]
Markopoulos, C. [7 ]
Hozumi, Y. [8 ]
Putter, H. [2 ]
Jones, S. E. [9 ]
机构：
[1] Univ Med Ctr, Freiburg, Germany
[2] Univ Med Ctr, Leiden, Netherlands
[3] Erasmus MC, Rotterdam, Netherlands
[4] Univ Birmingham, Birmingham, W Midlands, England
[5] Inst Sein Henri Hartmann, Neuilly Sur Seine, France
[6] Univ Hosp Gasthuisberg, Louvain, Belgium
[7] Univ Med Sch, Athens, Greece
[8] Jichi Med Univ, Shimotsuke, Japan
[9] US Oncol Res, Med Oncol, Houston, TX USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70047-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [21] A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer
    Krop, Ian
    Abramson, Vandana
    Colleoni, Marco
    Traina, Tiffany
    Holmes, Frankie
    Garcia-Estevez, Laura
    Hart, Lowell
    Awada, Ahmad
    Zamagni, Claudio
    Morris, Patrick G.
    Schwartzberg, Lee
    Chan, Stephen
    Gucalp, Ayca
    Biganzoli, Laura
    Steinberg, Joyce
    Sica, Lorenzo
    Trudeau, Maureen
    Markova, Denka
    Tarazi, Jamal
    Zhu, Zhou
    O'Brien, Thomas
    Kelly, Catherine M.
    Winer, Eric
    Yardley, Denise A.
    CLINICAL CANCER RESEARCH, 2020, 26 (23) : 6149 - 6157
  • [22] The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
    Beaver, Julia A.
    Park, Ben H.
    FUTURE ONCOLOGY, 2012, 8 (06) : 651 - 657
  • [23] A Pilot Study of Estradiol Followed by Exemestane for Reversing Endocrine Resistance in Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer
    Chalasani, Pavani
    Stopeck, Alison
    Clarke, Kathryn
    Livingston, Robert
    ONCOLOGIST, 2014, 19 (11): : 1127 - 1128
  • [24] DISTANT RECURRENCES AT MEDIAN OF 5-YEARS AMONG 9.779 POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE EARLY BREAST CANCER TREATED ON THE TEAM TRIAL OF ADJUVANT ENDOCRINE THERAPY
    Nortier, H.
    Hille, E.
    Rea, D.
    Seynaeve, C.
    Hasenburg, A.
    Vannetzel, J.
    Dirix, L.
    Markopoulos, C.
    van de Velde, C.
    Jones, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 78 - 78
  • [25] Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer
    Gil J.M.
    Rubio-Terrés C.
    del Castillo-Saiz A.
    González P.
    Canorea F.
    Clinical and Translational Oncology, 2006, 8 (5) : 339 - 348
  • [26] A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer
    Freedman, O. C.
    Amir, E.
    Dranitsaris, G.
    Dowsett, M.
    Cole, D. E. C.
    Kahn, H.
    O'Malley, F.
    Verma, S.
    Clemons, M.
    BREAST CANCER RESEARCH, 2009, 11 : S20 - S20
  • [27] Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer
    Francisco J. Esteva
    Stacy L. Moulder
    Ana M. Gonzalez-Angulo
    Joe Ensor
    James L. Murray
    Marjorie C. Green
    Kimberly B. Koenig
    Mong-Hong Lee
    Gabriel N. Hortobagyi
    Sai-Ching Yeung
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 63 - 72
  • [28] A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer
    OC Freedman
    E Amir
    G Dranitsaris
    M Dowsett
    DEC Cole
    H Kahn
    F O'Malley
    S Verma
    M Clemons
    Breast Cancer Research, 11
  • [29] Final Analysis of NCIC CTG MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary Breast Cancer
    Goss, P. E.
    Ingle, J. N.
    Chapman, J-A W.
    Ellis, M. J.
    Sledge, G. W.
    Budd, G. T.
    Rabaglio, M.
    Gelmon, K.
    Shepherd, L.
    Pritchard, K. I.
    CANCER RESEARCH, 2010, 70
  • [30] Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer A Randomized Clinical Trial
    Serrano, Davide
    Gandini, Sara
    Thomas, Parjhitham
    Crew, Katherine D.
    Kumar, Nagi B.
    Vornik, Lana A.
    Lee, J. Jack
    Veronesi, Paolo
    Viale, Giuseppe
    Guerrieri-Gonzaga, Aliana
    Lazzeroni, Matteo
    Johansson, Harriet
    D'Amico, Mauro
    Guasone, Flavio
    Spinaci, Stefano
    Bertelsen, Bjorn-Erik
    Mellgren, Gunnar
    Bedrosian, Isabelle
    Weber, Diane
    Castile, Tawana
    Dimond, Eileen
    Heckman-Stoddard, Brandy M.
    Szabo, Eva
    Brown, Powel H.
    DeCensi, Andrea
    Bonanni, Bernardo
    JAMA ONCOLOGY, 2023, 9 (05) : 664 - 672
12345